Exploiting a host immune response against various tumors and tumor antigens is a significant approach to block the initiation of cancer in genetically predisposed patents and to also block the recurrence of cancer in patients in remission. The current technology is a composition of matter invention that exploits the programming of human dendritic cells to mount a host immune response against a variety of different tumor types. The antigens are key serine proteases which are associated with tumor invasion and spread. Computer algorithms have been used to identify extended peptides that posses multiple epitopes recognized by T-lymphocytes.
Researchers have disclosed inventions consisting of the dendritic cells loaded with synthetic peptides specific to key antigens of cancer cells. The antigens targeted include hepsin, matriptase and stratum corneum chymotryptic enzyme. The host response generated by these programmed homologous dendritic cells is anticipated to trigger an immuno-cytotoxic response, sufficient to kill cancer cells, and to prevent their recurrence.
U.S. Patent Application #11/986,352
Seeking Licensing Partner to develop and commercialize this technology
License Status: Available for exclusive licensing
Mr. Christopher Fasel
Associate Director or Licensing
UAMS BioVentures - TLO
Medical School - Teaching Hospital - Research InstitutionView profile
Clients in focus...